In a report released today, Serge Belanger from Needham maintained a Hold rating on Omeros (OMER – Research Report). The company’s shares closed yesterday at $3.95.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Belanger is a 2-star analyst with an average return of -0.1% and a 38.63% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Cytokinetics, Liquidia Technologies, and BioCryst.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Omeros with a $45.00 average price target.
The company has a one-year high of $13.60 and a one-year low of $3.27. Currently, Omeros has an average volume of 830.5K.
Read More on OMER: